Which adipokines are associated with chronic inflammation in hypertensive patients with obesity? A pilot study

Anna Stępień, Mariusz Stępień, Rafał N. Wlazeł, Marek Paradowski, Piotr Bartnicki, Małgorzata Koziarska-Rościszewska, Magdalena Rysz-Górzyńska


Objective. The study was perform to assess the association between serum levels of adipokines and chronic inflammation  in non-diabetic hypertensive patients with obesity.

Methods. 54 patients aged 58±11 years were divided according to BMI into 3 groups of obesity classes: A – class I (n=25); B – class II (n=14); and C – class III (n=15). The patients were also divided into groups receiving statins or fibrates (n=31) or not (n=23).

Results. Leptin was higher in group C compared to A and B (62.0±32.1 ng/ml vs. 32.7±21.5 ng/ml; p<0.01 and vs. 36.1±16.4 ng/ml; p<0.05; respectively); hsCRP was higher in group C than in A (3.8±1.7 mg/l vs. 2.1±1.6 mg/l; p<0.01). Resistin, hsCRP and IL-6 were higher in the patients without hypolipidemic treatment (1.11±0.42 ng/ml vs. 0.89±0.26 ng/ml, p<0.05; 3.4±1.9 mg/l vs. 2.4±1.9 mg/l, p<0.05 and 16.1±7.3 pg/ml vs. 13.5±10.3 pg/ml; p<0.01 respectively).

Leptin correlated with hsCRP in the whole study population (r=0.318, p<0.05), in patients  receiving hypolipidemic therapy (r=0.434, p<0.05) and with TNF-a in group C (r=0.506, p=0.05).

Conclusions. Leptin is associated with chronic inflammation in hypertensive patients with obesity. Hypolipidemic treatment may reduce chronic inflammation not only by decreasing hsCRP and IL-6 circulating levels but also by lowering resistin serum level.


obesity, hypertension, inflammation, adipokines, hypolipidemic treatment


Al-Hamodi, Z., AL-Habori, M., Al-Meeri, A., Saif-Ali, R., 2014. Associations of adipokines, leptin/adiponectin ratio and C-reactive protein with obesity and type 2 diabetes mellitus. Diabetology & Metabolic Syndrome 6: 99.

Belfort, R., Berria, R., Cornell, J., Cusi, K., 2010. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J. Clin. Endocrinol. Metab. 95: 829-836.

Choi, J., Joseph, L., Pilote, L., 2012. Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obesity Rev. 14: 232-244.

Coelho, M., Oliveira, T., Fernandez, R., 2013. Biochemistry of adipose tissue: an endocrine organ. Arch. Med. Sci. 9: 191-200.

de Oliveira, L. V, Mafra, D., 2013. Adipokines in obesity. Clin. Chim. Acta 419: 87-94.

Dupuy, A.M., Badiou, S., Descomps, B., Cristol, J.P. 2003. Immuniturbidimetric determination of C-reactive protein (CRP) and high-sensitivity CRP on heparin plasma. Comparison with serum determination. Clin Chem. Lab. Med. 41: 948-9.

Ishii, S., Karlamangla, A.S., Bote, M., Irwin, M.R., Jacobs, D.R., Cho, H.J., Seeman, T.E., 2012. Gender, obesity and repeated elevation of C-reactive protein: data from the CARDIA Cohort. PLOS ONE 7: e36062. doi:10.1371/journal.pone.0036062

Jung, U.J., Choi M.S. 2014. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int. J. Mol. Sci. 15: 6184-6223; doi: 10.3390/ijms15046184.

Katsiki, N., Nikoloc, D., Montalto, G., Banach, M., Mikhailidis, D.P., Rizzo, M., 2013. The role of fibrate treatment in dyslipidemia: an overview. Curr. Pharmaceut. Des. 19: 3124-31.

Kshatriya, S., Liu, K., Salah, A., Szombathy, T., Freeman, R.H., Reams, G.P., Freeman, R.H., 2011. Obesity hypertension: the regulatory role of leptin. Int. J. Hypertens. ID 270624, 8 pages; doi:10.4061/2011/270624.

Łabuzek, K., Bułdak, Ł., Duława-Bułdak, A., Bielecka, A., Krysiak, R., Madej, A., Okopień, B., 2011. Atorvastatin and fenofibric acid differentially affect the release of adipokines in the visceral and subcutaneous cultures of adipocytes that were obtained from patients with and without mixed dyslipidemia. Pharmacol. Rep.63: 1124-1136.

Mahadik, S.R., 2012. Association between adipocytokines and insulin resistance in Indian hypertensive patients. Indian Heart J. 64: 35-39.

Mancuso P. 2016. The role of adipokines in chronic inflammation. ImmunoTargets and Therapy 5: 47-56.

Martins MC, Faleiro LL, Fonseca A. Relationship between leptin and body mass and metabolic syndrome population. Rev. Port. Cardiol. 2012; 31(11): 711-719.

Molica, F., Morel, S., Kwak, B.R., Rohner-Jeanrenaud F., Steffens S. 2015. Adipokines at the crossroad between obesity and cardiovascular disease. Thromb. Haemost. 113: 553-566.

Nutall, F. 2015. Body Mass Index. Obesity, BMI and health: a critical review. Nutr. Res. 50: 117-128.

Otto, C., Otto, B., Frost, R.J.A., Vogesser, M., Pfeiffer, A.F.H., Spranger, J., Parhofer K.G. 2007. Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. Acta Diabetol. 44: 65-68.

Ouchi, N., Parker, J.L., Lugus, J.J., Walsh, K. 2011. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 11: 85-97.

Park, O,Y., Kim, S,H., Ahn, Y.K., Yun, N.S., Kim, J.H., Sim D.S., Hong, Y.J., Kim, J.H., Ahn, Y., Jung Chaee Kanget, Y.C. 2008. Statin reduces C-reactive protein and interleukin-6 in normocholesterolemic patients with acute coronary syndrome. Chonnam Med. J. 44: 13-16.

Paul, R.F., Hassan, M., Nazar, H.S., Giliani, S., Afzal, N., Qayyum, I. 2011. Effect of body mass index on serum leptin levels. J. Ayub. Med. Coll. Abbattabad. 23: 40-43.

Rajkovic, N., Zamaklar, M., Lalic, K. 2014. Relationship between obesity, adipokines and inflammatory markers in type 2 diabetes: relevance for cardiovascular risk prevention. Int. J. Environ. Res. Public Health 11: 4049-4065.

Stępień, M., Rośniak-Bąk, K., Paradowski, M., Misztal, M., Kujawski, K., Banach, M., Rysz, J. 2011. Waist circumference, ghrelin and selected adipose tissue-derived adipokines as predictors of insulin resistance in obese patients. Med. Sci. Monit. 17: 13-18.

Stępień, M., Stępień, A., Wlazeł, R.N., Paradowski, M., Banach, M., Rysz, J. 2014a. Obesity indices and inflammatory markers in obese non-diabetic normo- and hypertensive patients: a comparative pilot study. Lipids in Health and Disease 13: 29; Doi:10.1186/1476-511X-13-29.

Stępień, M., Stępień. A., Banach, M., Wlazeł, R.N., Paradowski, M., Rizzo, M., Toth, P.P., Rysz, J. 2014b. New obesity indices and adipokines in normotensive patients and patients with hypertension. Comparative pilot analysis. Angiology 65: 333-342.

Stępień, M., Stępień, A., Wlazeł, R.N., Paradowski, M., Rizzo, M., Banach, M., Rysz, J. 2014c. Predictors of insulin resistance in patients with obesity: a pilot study. Angiology 65: 22-30.

Stępień, M., Wlazeł, R.N., Paradowski, M., Banach, M., Rysz, M., Misztal, M., Rysz, J. 2012. Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo- and hypertensive patients – pilot study. Arch. Med. Sci.8: 431-436.

Wanders, D., Plaisance, E.P., Judd, R.L. 2010. Pharmacological effects of lipid-lowering drugs on circulating adipokines. World J. Diabetes 1: 116-128.


  • There are currently no refbacks.